Insulin-like growth factor 1 has been studied in 99 papers since 1989: 2 trials and 13 observational studies in people, 38 in animals, 8 in cells, 37 reviews; 14 in the past year. Its furthest trials in people are at phase 2. The newest story, Oct 2, 2026: “IGF-1 and SLC25A33 preserve cochlear blood barrier integrity in aged mice”.
Insulin-like growth factor 1 extends lifespan in one study of Zmpste24(-/-) progeroid mice but shortens it in a study of insecticide-susceptible A. arabiensis. Independent labs report both increased and decreased cellular senescence in cells; one group reports human associations, including lower mortality in women but no clear mortality link in men. A paper declares ties to Lumos Pharma.
100 findings in 56 papers from 1989 to 2026, 5 of them since April 2026
The findings reach people, from one lab or study; independent labs found the same change in cells. 40 independent labs in 17 countries; 1 trial, none about aging.
“suppressed pulsatile GH secretion (P = 0.003), burst mass (P = 0.025), burst number (P = 0.005)”
Cells: replicated by independent labs. Worms or flies, mice and humans: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
40 independent labs in 17 countries
6 findings against
1 trial, none about aging
Funders: National Institutes of Health and others
2 of 89 findings with company ties
Human trial2
Humans13
Animals37
Model organisms1
Cells8
In silico1
Studies in people
1 study gave insulin-like growth factor 1 to people and measured what changed.
↓downin A. arabiensis1↓downin L. animals1↑upin mice1
3 studies
Insulin-like growth factor 1 shortens lifespan in L. animals.
“In laboratory animals, the effects of IGF-1 on growth- and development (positive), reproduction (positive), and longevity (negative) are well established.”
Insulin-like growth factor 1 extends lifespan in Zmpste24(-/-) progeroid mice.
“recombinant IGF-1 treatment restores the proper balance between IGF-1 and GH in Zmpste24(-/-) mice, delays the onset of many progeroid features, and significantly extends the lifespan”
Insulin-like growth factor 1 showed no clear effect on oxidative damage to lipids in P. biarmicus (captive bearded reedlings under semi-natural conditions).
“while no treatment effect was apparent in females.”
Animalscaptive bearded reedlings under semi-natural conditionsslow-release biodegradable microspheresfemales
Studies link insulin-like growth factor 1 with 10 measures, among them mortality, gait variability and gait asymmetry index.
Mortality
↓downin humans1↑upin mice1HR 0.4
2 studies
Insulin-like growth factor 1 is linked with a lower risk of mortality in humans (per log2-transformed IGF1 doubling, adjusted for age and eGFR) (HR 0.40 (95% CI 0.24–0.65) per IGF1 doubling; p < 0.001).
“low IGF1 levels associate with an increased risk of all-cause mortality in female RTR”
Humansper log2-transformed IGF1 doubling, adjusted for age and eGFRmedian follow-up 5.4 yearsfemalesn = 277
Insulin-like growth factor 1 is associated with mortality in KO-HIT mice lacking tissue Igf1 expression, both sexes.
“increases in serum IGF-1 levels were associated with increased levels of lipid peroxidation products in serum and increased mortality rate at 18 months of age”
Animalsin KO-HIT mice lacking tissue Igf1 expression, both sexes
Insulin-like growth factor 1 is associated with gait speed in humans (per 1-SD increase in IGF-1, after adjustment for covariates) (β = 1.105, P = 0.025 per 1-SD increase in IGF-1).
“gait speed (β = 1.105, P = 0.025)”
Humansper 1-SD increase in IGF-1, after adjustment for covariatesn = 642
Insulin-like growth factor 1 is associated with multidimensional gait performance in humans after adjustment for covariates; community-dwelling older adults.
“Higher circulating IGF-1 levels are associated with better multidimensional gait performance in community-dwelling older adults.”
Humansafter adjustment for covariates; community-dwelling older adultsn = 642
Insulin-like growth factor 1 is associated with executive function in prediabetes (β = 0.115 [0.028, 0.202], p = 0.010).
“Higher IGF-1 concentrations were associated with better executive performance in individuals with prediabetes (β = 0.115 [0.028, 0.202], p = 0.010), but not in individuals with normoglycemia or T2DM.”
Insulin-like growth factor 1 is linked with a higher risk of estrogen receptor-positive breast cancer in humans (OR 1.38 (95% CI 1.14-1.68)).
“The ORs for a difference in IGF1 concentration between the highest and lowest fifth were 1.38 (95% CI 1.14-1.68) for oestrogen-receptor-positive tumours”
Targeting this pathway curbs mitochondrial oxidative stress and pericyte activation to partially restore auditory function in mouse models.Targeting this pathway curbs mitochondrial oxidative stress and pericyte activation to partially restore auditory function in mouse models.